Chemical Variations on the p53 Reactivation Theme

Area of Science:

• Oncology
• Molecular Biology
• Drug Discovery

Background:

• The p53 tumor suppressor gene (TP53) is crucial in preventing cancer, often inactivated in over 50% of malignancies.
• In tumors with wild-type p53, its function is frequently inhibited by overexpressed negative regulators like MDM2 and MDMX.
• Restoring p53 function is a key strategy for developing novel anticancer therapies.

Purpose of the Study:

• To provide an updated overview of small molecules designed to restore p53 function in cancer cells.
• To discuss strategies targeting the p53-MDMs interaction, wild-type p53, or mutated p53.
• To present optimization approaches for small molecules that have advanced to clinical trials.

Main Methods:

• Literature review of small molecules targeting p53 pathways.
• Analysis of compounds inhibiting p53-MDM interactions.
• Examination of agents directly targeting wild-type or mutated p53.

Main Results:

• Several classes of small molecules have been developed to reactivate p53.
• Inhibition of p53-MDM interactions is a validated approach.
• Direct targeting of wild-type and mutated p53 shows therapeutic potential.

Conclusions:

• Small molecules offer a viable approach to restore p53 tumor suppressor activity in cancer.
• Targeting p53-MDM interactions and p53 directly are promising therapeutic strategies.
• Optimization of these molecules is crucial for clinical success in cancer treatment.